CHD1 and prostate cancer: Chromodomain helicase DNA-binding protein 1 (CHD1) was selected for further analysis based on its high frequency of deletion in prostate cancer (Augello et al., 2019, Grasso et al., 2012, Ren et al., 2018, Robinson et al., 2015, Rodrigues et al., 2015, Shenoy et al., 2017, Zhao et al., 2017).